Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion type Assertion NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_head.
- NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion description "[Low-dose demethylating agents such as 5-aza-2'-deoxycytidine (decitabine, DAC) and 5-azacytidine (azacitidine, Vidaza) have been explored for the treatment of myelodysplasia, acute myeloid leukemia, and hemoglobinopathies since the early 1980s, aiming to revert a methylator phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_provenance.
- NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion evidence source_evidence_literature NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_provenance.
- NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion SIO_000772 16292549 NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_provenance.
- NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion wasDerivedFrom befree-20140225 NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_provenance.
- NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_assertion wasGeneratedBy ECO_0000203 NP625762.RAp59HHe-B1XKC8UaXUC6zi0QriEl5bYqqx7u1_8WiH60130_provenance.